Topic: checkpoint inhibitors
The series B equips execs that cut their teeth at top multinational drugmakers to advance autoimmune and cancer candidates through the clinic.
After raising more than $194 million in venture capital, Gritstone is looking to raise up to $80 million in its IPO.
The deal gives AbbVie the global rights to an anti-GARP antibody designed to block the immunosuppressive activity of regulatory T cells.
Harbour BioMed licensed a midphase PD-L1 antibody from Kelun Biotech for development and commercialization outside of Greater China.
Apexigen has raised $73 million for clinical testing of its lead CD40-targeting immuno-oncology candidate as well as to broaden its cancer pipeline.
NewLink has cut its headcount by a third to buy the time it needs to prove that—despite setbacks—its IDO inhibitor indoximod is still worth pursuing.
Last week’s biotech discoveries include a gut-coating pill that lowers glucose and prostate-tumor test to predict a good response to immunotherapy.
BMS is combining Opdivo and cabiralizumab, an anti-CSF-1 antibody, with Apexigen’s lead CD40 activator in an early-phase solid tumor study.
Idera Pharmaceuticals' TLR antagonist, IMO-8400, failed to improve skin symptoms in adults with dermatomyositis.
Oncologie launched operations in Boston and Shanghai with a $16.5 million seed round, aiming to deliver drugs to China and the U.S. simultaneously.